Ho-il Choi
Yuseong, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
PT320, a GLP-1 receptor agonist, mitigates nucleus accumbens-associated depression- and anxiety-like behaviors in MitoPark mice of Parkinson's disease.
Journal: Journal of Parkinson's disease
Published: August 12, 2026
Corrigendum to "Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury" [Neurobiology of Disease Volume 124 (2019) 439-453 /YNBDI_4338].
Journal: Neurobiology of disease
Published: June 18, 2024
PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease.
Journal: Frontiers in neuroscience
Published: April 30, 2020
Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.
Journal: Scientific reports
Published: July 22, 2019
Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.
Journal: Neurobiology of disease
Published: October 03, 2018
Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Journal: Scientific reports
Published: September 14, 2018
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Journal: Scientific reports
Published: March 06, 2018
A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Journal: Cell transplantation
Published: November 09, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026